Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01477489 · ClinicalTrials.gov registry record · Phase 1
Veliparib With Radiation Therapy in Patients With Inflammatory or Loco-regionally Recurrent Breast Cancer
A Phase 1 study, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT01477489 is a Phase 1 study that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 33 participants.
The verdict
NCT01477489, a Phase 1 study, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the maximum tolerated dose of veliparib that can be given while a patient is receiving radiation therapy.
Interventions
- DRUG Veliparib
- RADIATION Standard radiation treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2012-01 |
| Est. Completion | 2017-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01477489
The ClinicalTrials.gov registry entry for NCT01477489 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Veliparib is the first listed.
NCT01477489 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01477489 about?
NCT01477489 is a clinical study titled "Veliparib With Radiation Therapy in Patients With Inflammatory or Loco-regionally Recurrent Breast Cancer". The purpose of this study is to determine the maximum tolerated dose of veliparib that can be given while a patient is receiving radiation therapy.
What is the current status of trial NCT01477489?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2012-01. Estimated completion is 2017-10.
What interventions are being tested in trial NCT01477489?
The interventions under investigation include: Veliparib (DRUG), Standard radiation treatment (RADIATION).
Who is sponsoring clinical trial NCT01477489?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.